"Pfizer Inc.'s (PFE.NYS) withdrawal of its painkiller Bextra was not a total surprise and it is unlikely Bextra will return to the market, said Richard Evans, pharmaceuticals analyst at Sanford Bernstein.
'I think this should be the expected outcome,' Evans told CNBC Thursday.
"Earlier, Pfizer confirmed the U.S. Food and Drug Administration asked it to pull Bextra from the market amid worries of increased cardiovascular risk and to add so-called 'black box' warnings to another painkiller, Celebrex." [NewsRatings.com]
